Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD oral solution in children and adolescents with autism spectrum disorder
2020-002819-21Phase 2Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autism Spectrum Disorder (ASD) and anxiety disorder comparing Cannabidiol oral solution with Placebo (2 arms). Primary endpoint: Reduction in ASD symptom severity. Started Apr 2021; status: completed.
02
Drugs
cannabidiol
03
Conditions
Autism Spectrum Disorder (ASD)anxiety disorder
Beyond the preview
Go deeper on 2020-002819-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002819-21.